You just read:

Positive Data from Trovagene Phase 1b/2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference

News provided by

Trovagene, Inc.

Sep 30, 2019, 08:15 ET